TARPLIN, DOWNS & YOUNG, LLC

Lobbying for AMYLYX PHARMACEUTICALS · Company dedicated to the development of potential therapies for neurodegenerative diseases

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $40,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Health Issues

rare disease and access to innovation

Medicare/Medicaid

rare disease and access to innovation

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.